Related Experiment Video

Updated: Apr 22, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

9.6K

Plasma paraoxonase, oxidative status level, and their relationship with asthma control test in children with asthma

O Emin1, A Hasan2, D M Rusen3

  • 1Department of Pediatrics, Division of Pediatric Allergy, Bezmialem Vakif University, Istanbul, Turkey.

Allergologia Et Immunopathologia
|October 13, 2014
PubMed

Insights

Biomarkers like paraoxonase (PON1) and total oxidant status (TOS) may indicate uncontrolled asthma in children. Combining these with the Asthma Control Test aids in identifying children with poorly controlled asthma.

Area of Science:

  • Pediatric Pulmonology
  • Biochemistry
  • Clinical Diagnostics

Background:

  • Asthma control assessment is crucial, yet lacks systemic inflammation biomarkers.
  • Current methods for assessing asthma control need complementary objective measures.

Purpose of the Study:

  • To investigate plasma paraoxonase (PON1), total oxidant status (TOS), and total antioxidant status (TAS) in children with asthma.
  • To evaluate the utility of these biomarkers in identifying uncontrolled asthma in pediatric patients.

Main Methods:

  • Recruited 85 asthmatic children and 55 healthy controls, excluding confounding factors.
  • Measured plasma PON1, TOS, and TAS levels.
  • Utilized receiver operating characteristic (ROC) analysis to assess diagnostic potential.

Main Results:

  • Asthmatic children showed significantly higher TAS and TOS, and lower PON1 levels compared to controls (P<0.001).
  • PON1 and TOS demonstrated moderate diagnostic potential for uncontrolled asthma (AUC 0.679 and 0.645, respectively).
  • The Asthma Control Test (ACT) showed high diagnostic accuracy (AUC 0.972).

Conclusions:

  • Plasma PON1 and TOS may serve as systemic biomarkers for uncontrolled asthma in children.
  • Combining PON1 and TOS with the Asthma Control Test could improve the identification of uncontrolled asthma in pediatric populations.
Abstract

Keywords:
Asthma controlBiomarkerChildrenOxidant stressParaoxonase

More Related Videos

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples05:17

Fast and Specific Assessment of the Halogenating Peroxidase Activity in Leukocyte-enriched Blood Samples

Published on: July 28, 2016

9.4K
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

10.7K

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.6K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
26
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
22
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K